icad inc. (ICAD): Price and Financial Metrics


icad inc. (ICAD)

Today's Latest Price: $13.30 USD

0.26 (1.99%)

Updated Jan 19 4:00pm

Add ICAD to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 185 in Medical - Devices & Equipment

See all "A" rated Strong Buy stocks

ICAD Stock Summary

  • ICAD's price/sales ratio is 10.47; that's higher than the P/S ratio of 83.92% of US stocks.
  • With a year-over-year growth in debt of -51.63%, Icad Inc's debt growth rate surpasses just 5.94% of about US stocks.
  • In terms of twelve month growth in earnings before interest and taxes, Icad Inc is reporting a growth rate of 46.88%; that's higher than 80.75% of US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Icad Inc are MBII, FLDM, BCOV, APDN, and OBLN.
  • ICAD's SEC filings can be seen here. And to visit Icad Inc's official web site, go to www.icadmed.com.

ICAD Stock Price Chart Interactive Chart >

Price chart for ICAD

ICAD Price/Volume Stats

Current price $13.30 52-week high $15.31
Prev. close $13.04 52-week low $5.91
Day low $13.04 Volume 102,488
Day high $13.48 Avg. volume 133,260
50-day MA $11.76 Dividend yield N/A
200-day MA $10.67 Market Cap 305.81M

icad inc. (ICAD) Company Bio


iCAD, Inc. provides image analysis, workflow solutions, and radiation therapy for the early identification and treatment of cancer in the United States and internationally. It operates through two segments, Cancer Detection and Cancer Therapy. The company was founded in 1984 and is based in Nashua, New Hampshire.


ICAD Latest News Stream


Event/Time News Detail
Loading, please wait...

ICAD Latest Social Stream


Loading social stream, please wait...

View Full ICAD Social Stream

Latest ICAD News From Around the Web

Below are the latest news stories about Icad Inc that investors may wish to consider to help them evaluate ICAD as an investment opportunity.

iCAD to Participate in the LifeSci Partners 10th Annual Healthcare Corporate Access Event

New ProFound AI risk software, offering a 2-year projected risk score to be featuredNASHUA, N.H., Jan. 06, 2021 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will participate in the 10th Annual LifeSci Partners Corporate Access Event, January 6-8 and 11-14, 2021. Michael Klein, Chairman and CEO, will host 1x1 meetings and will participate in a panel, Innovations in Cancer Diagnostics, on Thursday, January 7th at 4pm EST.Mr. Klein’s focus in diagnostics will be on iCAD’s newly launched ProFound AI Risk offering. This new breast cancer screening capability is the first and only commercially available clinical decision support tool that provides an accurate 2-year risk ...

Yahoo | January 6, 2021

iCAD Announces Renowned Neuro-Oncologist Santosh Kesari, MD, PhD to Lead Post-Market Study for Treatment of Recurrent Glioblastoma (GBM) with FDA-cleared Xoft Brain IORT Technology to Support Clinical Adoption

International Multi-Center Study to Commence January 2021 University of Louisville’s Trial on IORT for Large Brain Lesion Treatments Accelerating First European Patient Treated for Brain Metastasis with Xoft IORT System NASHUA, N.H., Dec. 29, 2020 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the appointment of Santosh Kesari, MD, PhD, a world-renowned neuro-oncologist, as Principal Investigator of its International multi-center clinical trial evaluating the Xoft® Axxent® Electronic Brachytherapy (eBx®) System® as the sole radiation therapy to treat recurrent glioblastoma (GBM) following surgical excision of the malignancy. The study is planned to commence in January 2021 at...

Yahoo | December 29, 2020

What Percentage Of iCAD, Inc. (NASDAQ:ICAD) Shares Do Insiders Own?

A look at the shareholders of iCAD, Inc. ( NASDAQ:ICAD ) can tell us which group is most powerful. Insiders often own a...

Yahoo | December 23, 2020

Is ICAD A Good Stock To Buy Now?

Out of thousands of stocks that are currently traded on the market, it is difficult to identify those that will really generate strong returns. Hedge funds and institutional investors spend millions of dollars on analysts with MBAs and PhDs, who are industry experts and well connected to other industry and media insiders on top of that. Individual investors can piggyback […]

Yahoo | December 13, 2020

Solis Mammography Adopts iCAD’s ProFound AI Platform Powered by Panorama with Short-Term Breast Cancer Risk Assessment Solution

Agreement Positions Both Companies for Growth; Leading-edge AI Technology to be Installed Across Largest Independent Provider of Mammography and Breast Health Services’ NetworkNASHUA, N.H. and DALLAS, Dec. 10, 2020 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, and Solis Mammography, the largest independent provider of mammography and breast health services in the United States, today announced a five-year partnership whereby iCAD will provide Solis Mammography’s nationwide network with its latest artificial intelligence (AI) breast health solutions, including ProFound AI® for DBT and ProFound AI Risk, the first and only clinical decision support tool to provide an accurate two-year breast ca...

Yahoo | December 10, 2020

Read More 'ICAD' Stories Here

ICAD Price Returns

1-mo -6.86%
3-mo 25.71%
6-mo 32.47%
1-year N/A
3-year 269.44%
5-year 237.56%
YTD 0.76%
2020 69.88%
2019 110.00%
2018 7.56%
2017 6.50%
2016 -37.52%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7621 seconds.